Saol Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Saol Therapeutics's estimated annual revenue is currently $9M per year.
- Saol Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Saol Therapeutics has 45 Employees.
- Saol Therapeutics grew their employee count by -38% last year.
Saol Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.7M | 103 | 10% | N/A | N/A |
#2 | $12.9M | 64 | 12% | N/A | N/A |
#3 | $9M | 45 | -38% | N/A | N/A |
#4 | $21.3M | 106 | 8% | N/A | N/A |
#5 | $9M | 45 | 7% | N/A | N/A |
#6 | $39.8M | 198 | -14% | N/A | N/A |
#7 | $0.3M | 3 | 50% | $50M | N/A |
#8 | $14.7M | 73 | -11% | N/A | N/A |
#9 | $8M | 40 | -2% | N/A | N/A |
#10 | $16.3M | 81 | 3% | N/A | N/A |
What Is Saol Therapeutics?
Saol Therapeutics (pronounced ?Sail??) is a privately held specialty pharmaceutical company focused on providing therapies to patients with rare diseases. The company has a strategic emphasis on the neurology therapeutic area. For more information, please visit our website: www.saolrx.com.
keywords:N/AN/A
Total Funding
45
Number of Employees
$9M
Revenue (est)
-38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Saol Therapeutics News
2022-04-20 - Amneal Scores Second US Biosimilar Approval With Avastin ...
Amneal says an $83.5m deal to acquire Saol Therapeutics' baclofen franchise will also bring the firm an experienced institutional...
2022-03-22 - Saol Therapeutics and GeneDx, Inc. Collaborate to Detect ...
Saol is focused on clinical development activity in rare diseases, with a focus on mitochondrial disorders, as well as central nervous system...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.7M | 45 | 7% | N/A |
#2 | $8.2M | 45 | -13% | N/A |
#3 | $12M | 46 | 5% | N/A |
#4 | $15M | 46 | 28% | N/A |
#5 | $5.3M | 46 | 15% | N/A |
Saol Therapeutics Executives
Name | Title |
---|---|
Brian Nappi | Senior Vice President, Strategy |
Brian Jennette | Vice President Finance |
Melinda Koehler | VP, Operations & Compliance |